Sangamo Therapeutics, INC Form 4 insider transactions

Sangamo Therapeutics CEO Sandy Macrae disposed of 126,950 shares of common stock for mandatory tax withholding purposes following an RSU vesting event.

A Sangamo Therapeutics officer disposed of shares for mandatory tax withholding related to vested restricted stock units.

Sangamo Therapeutics' Principal Accounting Officer, Nikunj Jain, disposed of 6,708 shares of common stock to cover mandatory tax withholdings related to RSU vesting.

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, disposed of 6,708 shares of common stock for mandatory tax withholding purposes following an RSU vesting event.

Sangamo Therapeutics CEO Sandy Macrae surrendered 7,488 shares for mandatory tax withholding following the vesting of restricted stock units.

A Sangamo Therapeutics executive reported a routine disposition of shares for mandatory tax withholding following the vesting of restricted stock units.

Sangamo Therapeutics' SVP and Chief Legal Officer, Scott B. Willoughby, disposed of 1,434 shares of common stock for mandatory tax withholding related to RSU vesting.

Sangamo Therapeutics' SVP and CFO, Prathyusha Duraibabu, disposed of 1,792 shares of common stock for mandatory tax withholding purposes.

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer of SANGAMO THERAPEUTICS, INC., disposed of 1,792 common shares for mandatory tax withholding following an RSU vesting.

Sangamo Therapeutics' Chief Financial Officer, Prathyusha Duraibabu, reported a routine disposition of shares for tax withholding purposes following the vesting of restricted stock units.

Sangamo Therapeutics' President and CEO, Sandy Macrae, reported the disposition of 126,950 shares of common stock for mandatory tax withholding purposes related to the vesting of restricted stock units.

Scott B. Willoughby, SVP, Chief Legal Officer, and Secretary of Sangamo Therapeutics, Inc. (SGMO), reported the disposition of shares for mandatory tax withholding related to vested restricted stock units.

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, disposed of 31,866 shares of common stock to cover tax obligations related to a restricted stock unit vesting.

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, disposed of 6,708 shares of common stock for mandatory tax withholding related to restricted stock unit vesting.

Sangamo Therapeutics, Inc. Director Karen L. Smith was granted 25,000 restricted stock units and options to purchase 50,000 shares of common stock on June 12, 2025.

Sangamo Therapeutics, Inc. Director H. Stewart Parker was granted 25,000 restricted stock units and options to purchase 50,000 shares of common stock, aligning his interests with shareholders.

Sangamo Therapeutics, Inc. Director Kenneth J. Hillan was granted 25,000 shares of common stock as Restricted Stock Units and 50,000 stock options on June 12, 2025, as part of his compensation.

Sangamo Therapeutics, Inc. Director Robert Carey was granted 25,000 shares of common stock as Restricted Stock Units and 50,000 stock options on June 12, 2025, increasing his beneficial ownership.

Sangamo Therapeutics, Inc. Director James R. Meyers was granted 25,000 restricted stock units and options to purchase 50,000 shares of common stock, aligning his interests with the company's long-term performance.

John Markels, a Director at Sangamo Therapeutics, Inc., was granted 25,000 shares of common stock as Restricted Stock Units and 50,000 stock options with an exercise price of $0.503 on June 12, 2025.

Margaret A. Horn, a Director at Sangamo Therapeutics, Inc., was granted 25,000 restricted stock units and 50,000 stock options on June 12, 2025, as disclosed in a recent SEC Form 4 filing.

Sangamo Therapeutics Director Courtney Beers has reported the acquisition of 25,000 restricted stock units and 50,000 stock options, increasing her beneficial ownership in the company.

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, Inc., disposed of 723 shares of common stock for mandatory tax withholding purposes related to a restricted stock unit vesting.

Scott B. Willoughby, SVP, Chief Legal Officer, and Secretary of Sangamo Therapeutics, Inc., reported a disposition of 1,433 shares of common stock valued at $0.4733 per share on May 24, 2025, solely for mandatory tax withholding related to vested restricted stock units.

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, disposed of 1,792 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Sangamo Therapeutics' Chief Financial Officer, Prathyusha Duraibabu, reported the disposition of 1,792 shares of common stock for mandatory tax withholding related to the vesting of restricted stock units.

Sangamo Therapeutics' President and CEO, Sandy Macrae, reported the disposition of 7,488 common shares valued at $0.4733 per share to cover mandatory tax withholding obligations related to a restricted stock unit vesting.

Scott B. Willoughby, SVP, General Counsel & Secretary of Sangamo Therapeutics, sold shares to cover tax obligations related to vested restricted stock units.

Prathyusha Duraibabu, CFO of Sangamo Therapeutics, surrendered shares to cover tax obligations upon vesting of restricted stock units.

CEO Sandy Macrae disposed of shares to cover tax obligations related to vested restricted stock units, while still holding a significant number of shares.